Advanced NanoTherapies
Advanced NanoTherapies Raises Over $31M Series B for Dual-Drug Vascular Balloons
Advanced NanoTherapies announced $31M+ in Series B financing on June 2, 2026. Advanced NanoTherapies announced the closing of an oversubscribed Series B financing of more than $31 million, co-led by S3 Ventures and an undisclosed strategic investor.
Round details
The financing includes backing from S3 Ventures, T45 Fund. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $31M+
How the company plans to use the capital
The company said next steps include scaling up manufacturing to meet FDA IDE requirements and submitting U.S. IDEs for two coronary indications, in-stent restenosis and small-vessel de novo lesions. It also plans to complete the testing package and IDE for a U.S. below-the-knee early feasibility study, pursue a pivotal trial agreement with the FDA, and identify non-U.S. sites for early pivotal enrollment.
Why this matters for GTM teams
The company says its lead program, SirPlux Duo, has received FDA breakthrough designation and is not yet approved for commercial use.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Advanced NanoTherapies Series B announcement.
Company Info
Investors (2)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free